Author

Sarah B. Brand

Observed names: S. Brand, SARAH BRAND, Sarah B Brand, Sarah Brand

Observed institutions: University of Michigan, Erasmus MC

ORCID: 0000-0003-3116-5951

Observed ORCID: 0000-0003-3116-5951

OpenAlex ID: A5028502811

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK

2015 · Virginia Becerra, Alfredo Gracia, et al. · BMJ Open · 89

PDF

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

2021 · Odette S. Reifsnider, Anuraag R. Kansal, et al. · American Journal of Kidney Diseases · 52

Cost-Effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure

2020 · Odette S. Reifsnider, Anuraag R. Kansal, et al. · ESC Heart Failure · 29

PDF

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

2020 · Odette Reifsnider, Anuraag Kansal, et al. · Diabetes Obesity and Metabolism · 28

PDF

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

2021 · Odette S Reifsnider, Anuraag R Kansal, et al. · BMJ Open Diabetes Research & Care · 26

PDF

Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

2014 · Andreas Clemens, Siyang Peng, et al. · The American Journal of Cardiology · 23

PDF

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

2021 · Anuraag R. Kansal, Odette S. Reifsnider, et al. · Journal of Market Access & Health Policy · 18

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States

2021 · Odette S. Reifsnider, Pratik Pimple, et al. · Diabetes Obesity and Metabolism · 13

AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis

2015 · Seye Abogunrin, Sarah Brand, et al. · ClinicoEconomics and Outcomes Research · 6

PDF

Comparación del coste-utilidad de los anticoagulantes orales de acción directa en la prevención de ictus en la fibrilación auricular no valvular en España

2017 · Manuel Monreal Bosch, Stéphane Soulard, et al. · Revista de Neurología · 3

Pdb63 - Cost-effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of Empa-reg Outcome in the United Kingdom

2018 · O. Reifsnider, A. Kansal, et al. · Value in Health · 2

Quality of Life and Its Determinants in Patients With Adrenal Insufficiency: A Survey Study From Three Tertiary Centers in the United States

2021 · Dingfeng Li, Malavika Suresh, et al. · Journal of the Endocrine Society · 1

PDF

1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States

2020 · ODETTE REIFSNIDER, PRATIK PIMPLE, et al. · Diabetes · 1

Sat-296 Cost-effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Based on Subgroup of Empa-reg Outcome

2019 · O.S. Reifsnider, A. Kansal, et al. · Kidney International Reports · 1

Author response for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"

2021 · Odette S. Reifsnider, Pratik Pimple, et al.

Abstract 15929: Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States

2019 · Odette S. Reifsnider, M. Feldman, et al. · Circulation

61. AbobotulinumtoxinA in the management of cervical dystonia (CD) in the United Kingdom (UK): a budget impact analysis (BIA)

2014 · Jerome Dinet, Kamal Desai, et al. · Toxicon

Insulin Treatment for Hyperglycaemia in the Paediatric Intensive Care Unit: Better Glucose Control With a Nurse-driven Protocol?

2008 · Jennifer J. Verhoeven, Sarah Brand, et al. · Archives of Disease in Childhood

Works count: 18

Citation count: 292

H-index: 8

I10-index: 8